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The chimeric Japanese encephalitis/Dengue 2
virus protects mice from challenge
by both dengue virus and JEV virulent virus
Dear Editor
Dengue fever (DF) is the most signiﬁcant emerging arbovirus
disease, which is caused by four distinct serotypes of Dengue
viruses (DENV-1 to DENV-4). Serotype-speciﬁc immunity
does not confer cross-protection against secondary infec-
tions from heterologous serotypes, which leads to dengue
haemorrhagic fever (DHF) and dengue shock syndrome
(DSS) as a result of antibody-dependent enhancement (ADE)
of infection that is mediated by non-neutralizing, cross-reac-
tive antibodies (Kliks et al., 1989). The intense efforts to
develop a safe and efﬁcient DENV vaccine have involved
using a variety of traditional biological technologies in the past
50 years (Durbin et al., 2005; McArthur et al., 2008), yet no
commercial DENV vaccine has been generated until now.
Developing DENV vaccine has been a high priority of the
World Health Organization (WHO) (Chambers et al., 1997).
Both Dengue virus and Japanese encephalitis virus (JEV)
belong to the Flaviviridae. The JE attenuated live vaccine
(SA14-14-2) was licensed in 1989 in China. Its safety and
effectiveness have been demonstrated in large scale clinical
surveillance and practical application of 600 million doses for
more than 20 years in China and in Southeast Asian coun-
tries including Korea, Thailand and India (Yu, 2010). No
vaccine associated encephalitis cases were reported for this
JE vaccine, compared with 21 encephalitis cases associated
with vaccination with the yellow fever (YF) vaccine 17D
which is regarded as a safety vaccine (Monath et al., 1999).
In particular, its unique proﬁle of attenuated neurovirulence
stability ensures the safety of the JE live vaccine and
enables the utility of this live vaccine strain as a vector to
develop vaccines against other Flaviviruses. This strategy
has become feasible with the advent of reverse genetic
method that has been used to construct chimeric ﬂaviviruses
(Pletnev et al., 2002; Mathenge et al., 2004). This approach
has been used to prepare chimeric viruses YF/DENV (1–4)
and such viruses exhibit high immunogenicity and low viru-
lence (Chambers et al., 2003; Guirakhoo et al., 2004).
In this study, the prM/E genes of JEV SA14-14-2 in the
plasmid pACNR-JEV were replaced with the prM/E gene
from the DENV-2 PUO-218 strain to generate the plasmid
pACNR-JE/DENV-2 with the method reported by Li and
Yang (Li et al., 2014; Yang et al., 2016). Results show that
the restriction enzyme digestion of pACNR-JE/DENV-2
yielded the DNA fragments that were resolved by elec-
trophoresis as expected. The chimeric virus JE/DENV-2 was
produced by transfecting viral RNA into the BHK21 cells.
The titre of the chimeric virus was approximately 3.3
log10PFU/mL. The size of the plaques ranged from 1 to
2 mm in diameter, which was smaller than that of JEV
SA14-14-2 (2 to 3 mm in diameter) but larger than that of the
DENV-2 (0.5–1 mm in diameter) (Fig. 1A). The results indi-
cate that the chimeric virus is more like dengue virus rather
than JEV and it is possible that the prM/E determines the
size and formation of the plaque (Li et al., 2013).
As a vaccine candidate, it must be stable in passaging
process. Sequence of the produced chimeric viruses from
passage 1th to passage 14th was determined, which all
contained the 10,959 nucleotides in the complete genome of
the engineered JE/DENV-2 virus. No mutation was detected
prior to passage 10th. 4 mutations were detected from
passage 11th to 14th. They are at nucleotide position 39 (A
to T) in the 5′ UTR, position 1,531 (C to T) in the structural
protein E region resulting in a serine to phenylalanine
mutation, position 3,511 (A to T) in the non-structural protein
region resulting in a histidine to leucine mutation, and posi-
tion 3,468 (A to C) in the non-structural protein region
resulting in a methionine to leucine mutation.
Indirect immunoﬂuorescence staining was adopted to
detect the expression of viral proteins from chimeric virus
JE/DENV-2 and the parental viruses JEV SA14-14-2 and
DENV-2. The results showed that monoclonal antibody
against the DENV-2 E protein detected the expression of the
DENV-2 E protein in BHK21 cells that were infected with the
DENV-2 virus and chimeric virus JE/DENV-2, but not with
JEV (Fig. 1B top panel). Monoclonal antibody against the
JEV E protein detected the expression of JEV E protein only
in BHK21 cells infected by the JEV SA14-14-2 virus (Fig. 1B
mid panel). Monoclonal antibody against the JEV NS1 pro-
tein detected the expression of JEV NS1 protein in cells
infected by JEV SA14-14-2 or JE/DENV-2, but not by DENV-2
virus (Fig. 1B bottom panel). These results conﬁrm the
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successful expression of DENV-2 E protein from the chi-
meric virus JE/DENV-2 and indicate that the SA14-14-2 is a
good vector to express exogenous antigen (Li et al., 2013; Li
et al., 2014; Yang et al., 2016).
The growth kinetics of the JE/DENV-2 virus were deter-
mined by infecting PHK, Vero or C6/36 cells and the results
were compared to the replication data of the DENV-2 virus
NGC strain and the JEV SA14-14-2 virus. In PHK cells, the
JE/DENV-2 propagated to lower titres at all time points
compared to JEV which reached the peak titre of 7.3
log10PFU/mL at 48 h post-infection. Instead, JE/DENV-2
exhibited a replication proﬁle that was similar to that DENV-2.
The peak titres of JE/DENV-2 and DENV-2 were 4.5
log10PFU/mL and 5.4 log10PFU/mL at 36 h, respectively
(Fig. 2A). In Vero cells, JE/DENV-2 grew more rapidly than
DENV-2, yet the titres of JE/DENV-2 were generally low with
a peak value of 3.7 log10PFU/mL in 120 h despite of the dif-
ferent conditions that we tested. In contrast, JEV SA14-14-2
reached a peak titre of 6.6 log10PFU/mL at 96 h post-
infection. DENV-2 replicated very slowly at the early time
points compared to JEV, but was able to reach a peak titre of
approximately 6.2 log10PFU/mL at 120 h (Fig. 2B). In C6/36
cells, JE/DENV-2 propagated less efﬁciently than JEV and
DENV-2, and reached its peak titre of approximately 4.8 at
48 h post-infection compared to the peak titre of 7.2
log10PFU/mL for JEV SA14-14-2 at 72 h and the peak titre of
6.0 log10PFU/mL for DENV-2 at 72 h (Fig. 2C). We also
investigated the growth kinetics of JE/DENV-2 with different
M.O.I. in PHK cells. The virus reached its peak titre of 4.9
log10PFU/mL at 24 h post-inoculation with the 0.025 M.O.I.
and the peak titre of 5.5 log10PFU/mL at 48 h post-inocula-
tion with the 0.005 M.O.I. and the 0.001 M.O.I. (Fig. 2D). In
conclusion, the chimeric virus JE/DENV-2 propagates less
efﬁciently compared to its parental virus JEV and exhibits a
stronger or similar replication capacity compared to DENV-2.
Neurovirulence of the JE/DENV-2 virus was evaluated via
the intra-cerebral (i.c.) route inoculation of 4-weekoldKun-Min
mice. The neurovirulence result showed that LD50 (log10PFU)
of JE/DENV-2 was 2.7. The JE live vaccine strain SA14-14-2
































Figure 1. The diameter of plaque and viral proteins expression of JEV, JE/DENV-2 and DENV-2 in BHK21 cells. (A) The
formation and diameter of plaques in BHK21 cells. (B) BHK21 cells were infected with each of these three viruses.
Immunoﬂuorescence staining was performed using antibodies recognizing DENV-2 E protein (1:10 dilution, top panel), JEV E
protein (1:10 dilution, mid panel), or JEV NS1 protein (1:10 dilution, bottom panel). Mock represents no virus infection. DENV, dengue
virus; JEV, Japanese encephalitis virus; JE, Japanese encephalitis; E, envelope protein; NS: non-structural protein.
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neurovirulence effect in mice. This result comes as a surprise,
because both the parental viruses are avirulent to mice. No
mouse died in the neuroinvasiveness test performed with
JE/DENV-2 or SA14-14-2.
All mice used for immunogenicity study did not exhibit any
sign of illness or mortality over the period of observation. The
sera were treated for PRNTas described in other research. All
mice immunized with the JE/DENV-2 chimeric virus were
seroconverted to produce anti-DENV-2 antibody, based on
the antibody titre value of 1:10. Antibody titre from each group
was pooled to calculate geometric mean titres (GMTs). From
week 1, 3, 5, 7, 9 and week 11 post boosting, the GMT
reached 80, 92, 92, 80, 106 and 184, respectively. Differences
of GMTs over this interval were not statistically signiﬁcant.
We then investigated whether the JE/DENV-2 chimeric
virus is able to induce protection against neuroadapted
DENV-2 virus (NGC strain). For this purpose, mice were
immunized with the JE/DENV-2 virus of 4.5 log10PFU via
intra-peritoneal route (i.p.), followed by challenging via the i.c.
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Figure 2. The growth curve of the chimeric virus in PHK, Vero and C6/36 cells and the chimeric virus JE/DENV-2 confers
protection against neuroadapted DENV-2 virus (New Guinea strain, NGC) and JE virulent virus JEV/SA14. The growth curve of
DENV-2, JE/DENV-2 and JEV in PHK cells (A), Vero cells (B), C6/36 cells (C) and PHK cells (D) (different M.O.I.). Mice were
immunized with JE/DENV-2 via the i.p. route, or mock immunized (MEM). One month after immunization, mice were challenged via
the i.c. route with neuroadapted DENV-2 NGC strain virus (shown in E) or via i.p. inoculation with JEV/SA14 virus (shown in F). The
number of survived mice at each time point was recorded and plotted. M.O.I., multiplicity of infection; MEM, minimum essential
medium; PHK, primary hamster kidney.
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after immunization. The mice were observed for 2 additional
weeks. None of these mice manifested any signs of illness for
the one-month period before virus challenge. Results show
that eight of nine immunized mice resisted the challenge of
neuroadapted DENV-2 NGC strain, however, nine of ten
mock-immunized mice succumbed to the challenge (Fig. 2E).
Because the chimeric JE/DENV-2 virus was constructed
using JE SA14-14-2 as the vector, we suspected that mice
immunized with JE/DENV-2 might also be protected from the
challenge with JE virulent virus JEV/SA14, in which the prM/E
gene of JEV SA14-14-2 was replaced with that of JEV wild
type SA14. Some studies reported that antibody to JEV NS1
protein can provide immune protection against wild type JEV
(Li et al., 2012). To test this possibility, mice were immunized
with JE/DENV-2 and then challenged via the i.p. route with
JEV/SA14 of 6.6 log10PFU one month after immunization.
Themortality rate was 15% in the immunized group compared
to 71% in mock-immunize group (Fig. 2F). The results are
according with Li’s results (Li et al., 2013). Together, these
data demonstrate that immunization of mice with the chimeric
virus JE/DENV-2 elicits strong protection against infection by
either neuroadapted DENV-2 or virulent JEV/SA14.
In summary, results of this study demonstrate that the JE
live vaccine virus serves as a promising vector for engi-
neering ﬂavivirus vaccines. The chimeric virus causes neu-
rovirulence to mice via i.c. inoculation although the parent
virus is avirulent and the reason need to be elucidated in the
following work, meanwhile the neurovirulence in primate of
chimeric virus need to be studied. Most importantly, we
found that JE/DENV-2 may induce immunity protection
against not only DENV-2 but also JEV. This will provide new
sight to design vaccine to against Flavivirus.
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